News and Trends 17 Aug 2018
Novo Nordisk Buys British ‘Smart’ Insulin Diabetes Biotech in deal worth €702M
Novo Nordisk acquired the UK biotech Ziylo, which develops glucose-responsive insulin treatments for diabetes that act in response to changes in blood sugar levels. The Danish big-pharma, which is already a big player in the diabetes space, acquired the full rights to Ziylo’s technology in a deal worth up to €702M ($800M). Novo will use the […]